AOD 9604, MOTS-c, and Tesamorelin Dosage: What the Research Shows

AOD 9604, MOTS-c, and tesamorelin are three different compounds with three different dose ranges, and no combined "stack" protocol has ever been validated in human trials. In research settings, AOD-9604 is typically used at 250–500 mcg per day, MOTS-c at 5–10 mg per week, and tesamorelin at the FDA-approved 2 mg once daily. The numbers below describe published research, not a recommended regimen.

Typical Dosages at a Glance

The aod 9604 dosage most often cited in research summaries is 250–500 mcg injected subcutaneously once daily. MOTS-c and tesamorelin are dosed very differently because their half-lives and mechanisms of action are not alike.

Peptide	Common research dose	Frequency	Human trial data	FDA status
AOD-9604	250–500 mcg	Once daily, fasted	Limited; Phase IIb results modest	Not approved
MOTS-c	5–10 mg	2–3 times weekly	None published in humans	Not approved
Tesamorelin	2 mg	Once daily, subcutaneous	Phase 3 trials, 26–52 weeks	Approved (Egrifta)
Ipamorelin (adjunct)	100–300 mcg	1–3 times daily	Small human studies	Not approved

Tesamorelin is the only one of these three with an FDA-approved human indication. AOD-9604 and MOTS-c are sold as research chemicals and are not approved for human use in the United States.

What Each Peptide Actually Does

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191) designed to influence fat metabolism without raising blood sugar or IGF-1. Early trials reported small reductions in body fat, but the effect was not strong enough to win regulatory approval for weight loss.

An aod 9604 vs mots-c comparison usually comes down to mechanism: AOD-9604 is studied for lipolysis, while MOTS-c is studied for cellular energy regulation.

MOTS-c

MOTS-c is a mitochondrial-derived peptide that activates AMPK, an enzyme involved in energy balance. Most available data come from rodent studies showing improved insulin sensitivity and exercise capacity. No controlled human trials of MOTS-c have been published.

Tesamorelin

Tesamorelin is a growth hormone-releasing hormone analog given by subcutaneous injection. In Phase 3 trials of people with HIV-associated lipodystrophy, 2 mg daily reduced visceral adipose tissue by roughly 15–18% over 26 weeks while leaving subcutaneous fat largely unchanged.

That evidence gap shapes any aod 9604 vs tesamorelin comparison: one compound has regulatory approval and human outcome data, and the other does not.

Stacking: What People Mean by Combining Them

An aod-9604 mots-c tesamorelin stack is a research-only concept that combines a fat-metabolism fragment, a mitochondrial peptide, and a GHRH analog. Because no study has tested all three together, every dose schedule is guesswork rather than a proven protocol.

When people discuss an aod-9604 tesamorelin stack dosage, they typically keep tesamorelin at 2 mg daily and add AOD-9604 at 250–500 mcg earlier in the day. Ipamorelin, a ghrelin mimetic, is sometimes substituted for or added to the GHRH component to amplify growth hormone pulses.

Stacking also multiplies the unknowns. Overlapping effects on growth hormone, appetite, and glucose handling are hard to attribute to any single compound, which makes side effects difficult to trace.

Timing and Administration

• AOD-9604: usually taken fasted, 20–30 minutes before a meal, because food may blunt its effects in research models.
• MOTS-c: often dosed in the morning and split into 2–3 weekly injections in rodent-derived protocols.
• Tesamorelin: taken at bedtime in most clinical use, matching the body's natural overnight growth hormone release.
• Ipamorelin: sometimes paired with tesamorelin at night, since both act on growth hormone signaling.

Safety and Legal Status

Tesamorelin's prescribing information lists injection-site reactions, joint pain, peripheral edema, and possible increases in IGF-1, and it requires monitoring in clinical use. Anyone considering it should speak with a healthcare professional, especially if they have diabetes or a history of tumors.

AOD-9604 and MOTS-c have no approved human dose, no regulated supply chain, and no long-term safety data. Products sold online are frequently mislabeled or underdosed, and sterility is not guaranteed.

AOD-9604 and MOTS-c are not FDA-approved for human use in the United States, and tesamorelin is approved only for HIV-associated lipodystrophy.

Bottom Line

Each compound has its own dose range, half-life, and evidence base, so the three should never be collapsed into a single number. Tesamorelin has the strongest human data, AOD-9604 has modest trial results, and MOTS-c has almost none.

If you are researching these peptides, treat any combined schedule as experimental and discuss it with a licensed clinician before injecting anything.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical AOD 9604 dosage used in research?

Research summaries and trial protocols most often cite 250–500 mcg injected subcutaneously once daily, usually on an empty stomach. The Phase IIb studies of AOD-9604 used daily dosing for up to 12 weeks. There is no FDA-approved human dose, so these figures are experimental.

Is MOTS-c or tesamorelin better for fat loss?

Tesamorelin has published Phase 3 data showing reduced visceral fat in people with HIV-associated lipodystrophy, while MOTS-c has no controlled human trials at all. Neither is a general-purpose weight loss drug. The comparison favors tesamorelin on evidence alone, not on proven results for healthy adults.

Can you stack AOD 9604 with tesamorelin?

No validated human protocol exists for combining AOD-9604, MOTS-c, and tesamorelin. Researchers sometimes describe keeping tesamorelin at 2 mg daily while adding AOD-9604 earlier in the day, but overlapping effects on growth hormone and glucose make side effects hard to trace. Talk to a healthcare professional before considering any stack.